Ser-Pro : A dipeptide formed from L-serine and L-proline residues. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 4369021 |
| CHEMBL ID | 2371153 |
| CHEBI ID | 74820 |
| MeSH ID | M0439385 |
| Synonym |
|---|
| (2s)-1-[(2s)-2-amino-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid |
| CHEMBL2371153 |
| l-ser-l-pro |
| ser-pro |
| CHEBI:74820 , |
| serylproline |
| l-seryl-l-proline |
| l-proline, l-seryl- |
| 23827-93-2 |
| (s)-1-((s)-2-amino-3-hydroxypropanoyl)pyrrolidine-2-carboxylic acid |
| l-serinyl-l-proline |
| WBAXJMCUFIXCNI-WDSKDSINSA-N |
| h-ser-pro-oh |
| DTXSID90402478 |
| seryl-proline |
| mfcd00037333 |
| serinylproline |
| s-p dipeptide |
| serine-proline dipeptide |
| sp dipeptide |
| serine proline dipeptide |
| Q27144929 |
| CS-0655266 |
| HY-P4569 |
| l-proline,l-seryl- |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| dipeptide | Any molecule that contains two amino-acid residues connected by peptide linkages. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Glutamate receptor 1 | Homo sapiens (human) | Ki | 130.0000 | 0.0147 | 2.5037 | 9.2000 | AID92023 |
| Glutamate receptor 2 | Homo sapiens (human) | Ki | 130.0000 | 0.0168 | 1.2772 | 5.0000 | AID92023 |
| Glutamate receptor 3 | Homo sapiens (human) | Ki | 130.0000 | 0.0206 | 0.5322 | 2.2000 | AID92023 |
| Glutamate receptor ionotropic, kainate 3 | Rattus norvegicus (Norway rat) | Ki | 130.0000 | 0.0038 | 0.7975 | 4.1000 | AID92023 |
| Solute carrier family 15 member 1 | Homo sapiens (human) | Ki | 130.0000 | 0.1800 | 3.3933 | 9.8000 | AID92023 |
| Glutamate receptor 4 | Homo sapiens (human) | Ki | 130.0000 | 0.0400 | 1.2335 | 8.8500 | AID92023 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID92023 | Inhibition constant (Ki) for human intestinal peptide carrier | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Three-dimensional quantitative structure-activity relationship analyses of peptide substrates of the mammalian H+/peptide cotransporter PEPT1. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.64) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||